[Determination of optimal diphenylhydantoin dosage by monitoring serum concentrations]. 1980

M Weintraub, and H Halkin, and Y Shaked, and S Almog

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D011182 Postoperative Care The period of care beginning when the patient is removed from surgery and aimed at meeting the patient's psychological and physical needs directly after surgery. (From Dictionary of Health Services Management, 2d ed) Care, Postoperative,Postoperative Procedures,Procedures, Postoperative,Postoperative Procedure,Procedure, Postoperative
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M Weintraub, and H Halkin, and Y Shaked, and S Almog
March 1969, Die Medizinische Welt,
M Weintraub, and H Halkin, and Y Shaked, and S Almog
October 1987, Kaku igaku. The Japanese journal of nuclear medicine,
M Weintraub, and H Halkin, and Y Shaked, and S Almog
October 1971, Medical laboratory technology,
M Weintraub, and H Halkin, and Y Shaked, and S Almog
January 1973, Proceedings of the Australian Association of Neurologists,
M Weintraub, and H Halkin, and Y Shaked, and S Almog
February 1975, Clinical chemistry,
M Weintraub, and H Halkin, and Y Shaked, and S Almog
January 1978, Journal of the American Veterinary Medical Association,
M Weintraub, and H Halkin, and Y Shaked, and S Almog
April 1976, Der Nervenarzt,
M Weintraub, and H Halkin, and Y Shaked, and S Almog
October 1970, Clinica chimica acta; international journal of clinical chemistry,
M Weintraub, and H Halkin, and Y Shaked, and S Almog
September 1972, Journal of chromatography,
M Weintraub, and H Halkin, and Y Shaked, and S Almog
January 1971, European neurology,
Copied contents to your clipboard!